Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seifert
Wisplinghoff

Showing results (1-10 of 10,106) with videos related to

Pageof 1,011
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 1999
ReplySeifert, Wisplinghoff
Berliner Und Munchener Tierarztliche Wochenschrift|April 16, 2015
[Epidemiology and clinical features of Acinetobacter baumannii infections in humans]Hilmar Wisplinghoff, Harald Seifert
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 1999
Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patientsH Wisplinghoff, W Perbix, H Seifert
The Journal of Antimicrobial Chemotherapy|September 19, 2006
Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolatesHarald Seifert, Danuta Stefanik, Hilmar Wisplinghoff
Antimicrobial Agents and Chemotherapy|July 18, 2000
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strainsB Heinemann, H Wisplinghoff, M Edmond, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolatesPaul G Higgins, Will Stubbings, Hilmar Wisplinghoff, et al.
Journal of Clinical Microbiology|November 8, 2005
Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998Hilmar Wisplinghoff, Birgitta Ewertz, Susanne Wisplinghoff, et al.
Emerging Infectious Diseases|November 12, 2003
Small colony variants of Staphylococcus aureus and pacemaker-related infectionHarald Seifert, Hilmar Wisplinghoff, Petra Schnabel, et al.
Journal of Clinical Microbiology|October 1, 2010
gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3Paul G Higgins, Marlene Lehmann, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strainsPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Pageof 1,011

Showing results (1-10 of 10,106) with videos related to

Sort By:
Pageof 1,011
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 1999
ReplySeifert, Wisplinghoff
Berliner Und Munchener Tierarztliche Wochenschrift|April 16, 2015
[Epidemiology and clinical features of Acinetobacter baumannii infections in humans]Hilmar Wisplinghoff, Harald Seifert
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 1999
Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patientsH Wisplinghoff, W Perbix, H Seifert
The Journal of Antimicrobial Chemotherapy|September 19, 2006
Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolatesHarald Seifert, Danuta Stefanik, Hilmar Wisplinghoff
Antimicrobial Agents and Chemotherapy|July 18, 2000
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strainsB Heinemann, H Wisplinghoff, M Edmond, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2010
Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolatesPaul G Higgins, Will Stubbings, Hilmar Wisplinghoff, et al.
Journal of Clinical Microbiology|November 8, 2005
Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998Hilmar Wisplinghoff, Birgitta Ewertz, Susanne Wisplinghoff, et al.
Emerging Infectious Diseases|November 12, 2003
Small colony variants of Staphylococcus aureus and pacemaker-related infectionHarald Seifert, Hilmar Wisplinghoff, Petra Schnabel, et al.
Journal of Clinical Microbiology|October 1, 2010
gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3Paul G Higgins, Marlene Lehmann, Hilmar Wisplinghoff, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strainsPaul G Higgins, Hilmar Wisplinghoff, Danuta Stefanik, et al.
Pageof 1,011